151 related articles for article (PubMed ID: 16356090)
1. Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma.
Czepczyński R; Ziemnicka K; Baczyk M; Oleksa R; Ruchała M; Sowiński J
Thyroid; 2005 Nov; 15(11):1261-5. PubMed ID: 16356090
[TBL] [Abstract][Full Text] [Related]
2. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
3. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
[TBL] [Abstract][Full Text] [Related]
4. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
[TBL] [Abstract][Full Text] [Related]
5. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
6. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma.
Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN
Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520
[TBL] [Abstract][Full Text] [Related]
7. Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinomas treated with iodine 131.
Matovic MD; Jankovic SM; Jeremic M; Tasic Z; Vlajkovic M
Thyroid; 2009 Aug; 19(8):843-8. PubMed ID: 19519221
[TBL] [Abstract][Full Text] [Related]
8. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma.
Reiners C; Biko J; Haenscheid H; Hebestreit H; Kirinjuk S; Baranowski O; Marlowe RJ; Demidchik E; Drozd V; Demidchik Y
J Clin Endocrinol Metab; 2013 Jul; 98(7):3039-48. PubMed ID: 23616148
[TBL] [Abstract][Full Text] [Related]
9. Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay.
Hodgson DC; Brierley JD; Tsang RW; Panzarella T
Radiother Oncol; 1998 Jun; 47(3):325-30. PubMed ID: 9681898
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
[TBL] [Abstract][Full Text] [Related]
11. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
[TBL] [Abstract][Full Text] [Related]
12. A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer.
Bal C; Chandra P; Kumar A; Dwivedi S
Nucl Med Commun; 2012 Oct; 33(10):1039-47. PubMed ID: 22760303
[TBL] [Abstract][Full Text] [Related]
13. Use of fractionated doses of iodine-131 for ablation of thyroid remnants.
Wang SJ; Liu TJ
Zhonghua Yi Xue Za Zhi (Taipei); 2002 Jul; 65(7):336-40. PubMed ID: 12365652
[TBL] [Abstract][Full Text] [Related]
14. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
16. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
Silberstein EB
J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
[TBL] [Abstract][Full Text] [Related]
17. Outcome after high-dose radioiodine therapy for advanced differentiated thyroid carcinoma in childhood.
Gao YC; Lu HK
Endocr Res; 2009; 34(4):121-9. PubMed ID: 19878072
[TBL] [Abstract][Full Text] [Related]
18. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
19. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
20. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
